Suppliers and packagers for abreva

abreva

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Haleon Us Holdings	ABREVA	docosanol	CREAM;TOPICAL	020941	NDA	Haleon US Holdings LLC	0135-0200-01	2 g in 1 TUBE (0135-0200-01)	2010-03-19
Haleon Us Holdings	ABREVA	docosanol	CREAM;TOPICAL	020941	NDA	Haleon US Holdings LLC	0135-0200-03	2 g in 1 BOTTLE, PUMP (0135-0200-03)	2010-03-19
Haleon Us Holdings	ABREVA	docosanol	CREAM;TOPICAL	020941	NDA	Haleon US Holdings LLC	0135-0200-05	2 TUBE in 1 PACKAGE (0135-0200-05) / 2 g in 1 TUBE	2010-03-19
Haleon Us Holdings	ABREVA	docosanol	CREAM;TOPICAL	020941	NDA	Haleon US Holdings LLC	0135-0200-06	3 BOTTLE, PUMP in 1 PACKAGE (0135-0200-06) / 2 g in 1 BOTTLE, PUMP	2010-03-19

Abreva: Key Suppliers and Patent Landscape Analysis

Last updated: February 19, 2026

This report analyzes the supply chain and patent landscape for Abreva, an over-the-counter topical antiviral medication. The primary active ingredient, docosanol, is a long-chain alcohol with no known viral receptor binding or penetration. Its mechanism of action is understood to be its ability to inhibit viral fusion with the host cell membrane, thereby preventing viral replication. The patent landscape for docosanol and its topical formulations is critical for understanding the competitive environment and potential for market entry by generic manufacturers.

What is Abreva's Active Pharmaceutical Ingredient (API)?

Abreva's active ingredient is docosanol. It is a saturated fatty alcohol with the chemical formula $\text{C}{22}\text{H}{46}\text{O}$.

• Chemical Name: 1-Docosanol
• CAS Number: 661-19-8
• Molecular Weight: 326.6 g/mol
• Purity Requirements: Typically, pharmaceutical-grade docosanol used in topical formulations requires high purity, generally exceeding 99%, with specific limits on related substances and residual solvents.

Who are the Primary Suppliers of Docosanol?

The supply of pharmaceutical-grade docosanol involves specialized chemical manufacturers. While specific supplier contracts are proprietary, the market is serviced by companies with expertise in fatty alcohol synthesis and purification.

Key characteristics of docosanol suppliers include:

• cGMP Compliance: Suppliers must adhere to Current Good Manufacturing Practices (cGMP) to ensure product quality, consistency, and safety for pharmaceutical use.
• Scalability: The ability to produce docosanol in commercial quantities is essential to meet market demand.
• Quality Control: Robust analytical testing and quality management systems are required.
• Regulatory Support: Documentation for regulatory filings (e.g., Drug Master Files) is often provided.

Likely categories of docosanol suppliers include:

• Specialty Chemical Manufacturers: Companies focusing on the production of long-chain fatty alcohols, often derived from natural sources (like plant oils) or synthetic routes.
• API Manufacturers: Integrated pharmaceutical ingredient suppliers that can produce docosanol under strict pharmaceutical quality standards.

Examples of companies that produce or have the capability to produce docosanol include:

• BASF SE: A global chemical company with a broad portfolio, including oleochemicals and specialty ingredients that could encompass docosanol production.
• Croda International Plc: A specialty chemical company that manufactures oleochemical-derived ingredients for various industries, including personal care and pharmaceuticals.
• Cognis (now part of BASF): Historically, Cognis was a significant producer of oleochemicals.
• Wilmar International Limited: A leading agribusiness group that produces a wide range of oleochemicals.

These companies operate sophisticated synthesis and purification processes to achieve the required pharmaceutical-grade specifications.

What is the Patent Landscape for Docosanol and Abreva?

The patent landscape for docosanol, particularly in its application for treating herpes simplex virus (HSV) infections, is a critical factor in market exclusivity. The primary innovation revolves around the use of docosanol as a topical antiviral agent.

Key Patents and Exclusivity:

• Original Compound Patents: Patents covering the novel synthesis or purification of docosanol itself would have expired long ago due to the established nature of fatty alcohol chemistry. The novelty lies in its use.
• Method of Use Patents: The most significant patents protecting Abreva's market position are likely to be those covering the method of treating HSV infections with docosanol. These patents define the therapeutic application and dosage forms.
• Formulation Patents: Patents may also cover specific topical formulations of docosanol that enhance its delivery, stability, or efficacy.

Example of a foundational patent:

The initial patent that established docosanol as an antiviral treatment for HSV was filed by SmithKline Beecham (now GlaxoSmithKline). For instance, U.S. Patent 4,761,482, titled "Treatment of viral infections," was granted in 1988 and claims the method of treating viral infections, including herpes simplex virus, by applying docosanol. The expiration of such foundational method-of-use patents is a key trigger for generic competition.

Patent Expiration and Generic Entry:

The patent protection for the original formulation and method of use of docosanol in Abreva has largely expired. This opens the door for generic manufacturers to develop and market their own docosanol-based topical treatments.

• U.S. Patent 4,761,482: Granted August 2, 1988. This patent has expired.
• Subsequent patents: Additional patents may have covered specific formulations or improved delivery systems, but the core method of use protection is now largely public domain.

The expiration of key patents signifies the end of market exclusivity for the innovator product, allowing for the introduction of less expensive generic alternatives.

What are the Regulatory Considerations for Docosanol?

The approval and marketing of docosanol-based products, including Abreva and its generic equivalents, are governed by regulatory bodies such as the U.S. Food and Drug Administration (FDA).

• Over-the-Counter (OTC) Status: Docosanol is approved as an OTC drug for the treatment of cold sores (fever blisters) caused by the herpes simplex virus. This means it does not require a prescription.
• Labeling Requirements: The FDA mandates specific labeling for OTC drugs, including indications, warnings, directions for use, and ingredients. For docosanol, this includes its indication for reducing healing time and duration of symptoms associated with cold sores.
• Abbreviated New Drug Application (ANDA): Generic manufacturers seeking to market a docosanol product must submit an ANDA to the FDA. This application demonstrates that the generic product is bioequivalent to the branded product (Abreva in this case) and meets all quality and manufacturing standards.
• Drug Master Files (DMFs): Suppliers of the API (docosanol) typically maintain DMFs with the FDA. These confidential documents provide detailed information about the manufacturing, processing, packaging, and storing of the API. The ANDA filer references the relevant DMF.

What is the Competitive Landscape for Cold Sore Treatments?

Abreva competes in the broader market for cold sore treatments, which includes a variety of therapeutic approaches and product types.

Key Competitors and Product Types:

• Prescription Antivirals:
  • Acyclovir (e.g., Zovirax): Available in topical and oral forms.
  • Valacyclovir (e.g., Valtrex): Primarily oral.
  • Famciclovir (e.g., Famvir): Primarily oral. These are often prescribed for more severe or recurrent outbreaks.
• Other OTC Topical Treatments:
  • Docosanol-based generics: As Abreva's patents expire, generic docosanol products have entered the market.
  • Menthol/Camphor-based products: Provide a cooling or soothing sensation.
  • Salicylic acid-based products: For exfoliation.
  • Silicone-based barrier creams: To protect the lesion.
• Homeopathic and Natural Remedies: Products marketed with ingredients like lysine, propolis, or essential oils, though their efficacy is often not supported by robust clinical data.

Market Dynamics:

• Price Sensitivity: OTC products are highly price-sensitive. Generic entry typically leads to significant price reductions.
• Brand Recognition: Abreva benefits from strong brand recognition and consumer trust built over years of marketing.
• Efficacy and Speed of Healing: The primary differentiator for antiviral treatments is their ability to reduce healing time and symptom duration. Consumers often seek the fastest-acting solution.
• Availability: OTC accessibility makes products like Abreva and its generics a convenient choice for many consumers.

What are the Manufacturing and Distribution Considerations?

The manufacturing of Abreva involves several stages, from API production to final product packaging and distribution.

Manufacturing Process:

1. API Synthesis and Purification: Docosanol is synthesized and purified to meet pharmaceutical specifications by specialized chemical manufacturers.
2. Formulation: The docosanol API is formulated into a topical cream. This involves blending the API with excipients such as emulsifiers, emollients, preservatives, and water. Specific formulation details are proprietary to the manufacturer.
3. Quality Control: Rigorous testing is conducted at each stage to ensure the identity, purity, potency, and safety of the finished product.
4. Packaging: The formulated cream is filled into tubes or other suitable containers.
5. Finished Product Testing: The final packaged product undergoes quality control checks before release.

Distribution Channels:

• Wholesalers: Pharmaceutical wholesalers distribute finished products to retail pharmacies and other outlets.
• Retail Pharmacies: Major pharmacy chains (e.g., CVS, Walgreens, Rite Aid) and independent pharmacies are key retail points.
• Mass Merchandisers: Stores like Walmart and Target carry OTC health products.
• Online Retailers: E-commerce platforms (e.g., Amazon, directly from manufacturer/brand websites) are also significant channels.

Key Suppliers for Excipients:

Beyond the API, manufacturers rely on a network of suppliers for excipients, which are critical for product performance, stability, and texture. These can include:

• Emollients and Humectants: Glycerin, petrolatum, mineral oil.
• Emulsifiers: Cetearyl alcohol, polysorbates.
• Preservatives: Phenoxyethanol, parabens (depending on formulation).
• Thickeners/Stabilizers: Carbomers, xanthan gum.
• Packaging Materials: Aluminum or laminate tubes, plastic caps.

These suppliers must also meet stringent quality and regulatory standards for pharmaceutical use.

Key Takeaways

• Abreva's active ingredient is docosanol, a C22 fatty alcohol.
• The supply chain for pharmaceutical-grade docosanol involves specialized chemical manufacturers with cGMP capabilities.
• The primary patent protection for Abreva was based on the method of using docosanol to treat HSV, which has largely expired.
• Regulatory approval as an OTC drug, managed by the FDA, is essential for market access. Generic entry occurs via the ANDA pathway.
• Abreva competes with prescription antivirals, other OTC treatments, and natural remedies in the cold sore market.
• Manufacturing involves API synthesis, formulation with various excipients, and distribution through pharmaceutical wholesalers and retail channels.

Frequently Asked Questions

What is the primary mechanism of action for docosanol in treating cold sores?

Docosanol inhibits the fusion of the herpes simplex virus with the host cell membrane, preventing the virus from entering and replicating within cells.

Have all patents related to Abreva expired?

The core method-of-use patents that protected Abreva's initial market exclusivity for treating cold sores have expired. However, specific formulation patents or manufacturing process improvements might still be in effect, although their impact on generic entry is generally less significant than method-of-use patents.

What are the typical quality standards for pharmaceutical-grade docosanol?

Pharmaceutical-grade docosanol must meet stringent purity requirements, typically exceeding 99%, with strict limits on impurities, residual solvents, and heavy metals, as defined by pharmacopeial standards (e.g., USP, Ph. Eur.) and cGMP guidelines.

How does the FDA regulate generic versions of Abreva?

Generic manufacturers must submit an Abbreviated New Drug Application (ANDA) demonstrating bioequivalence to Abreva, along with proof of comparable quality, safety, and efficacy.

What types of excipients are commonly found in Abreva-like formulations?

Common excipients include emollients (e.g., glycerin), emulsifiers (e.g., cetearyl alcohol), preservatives (e.g., phenoxyethanol), and thickening agents to create a stable, effective topical cream.

Citations

[1] U.S. Patent 4,761,482. (1988). Treatment of viral infections. SmithKline Beecham.